| Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice. | gastric, |
| Physical and transcriptional map of a 311-kb segment of chromosome 18q21, a candidate lung tumor suppressor locus. | lung, |
| Status of the DPC4 tumor suppressor gene in sporadic colon adenocarcinoma of Croatian patients: identification of a novel somatic mutation. | colorectal, |
| Infrequent alteration of the DPC4 tumor suppressor gene in renal cell carcinoma. | kidney, |
| Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. | breast, |
| These results provide genetic confirmation that SMAD4 is a pancreatic ductal adenocarcinoma tumor suppressor, functioning to block the progression of KRAS(G12D)-initiated neoplasms. | pancreatic,neoplasm, |
| Inactivation of SMAD4 tumor suppressor gene during gastric carcinoma progression. | gastric, |
| Concomitant expression of Kras(G12D) and haploinsufficiency of the Smad4/Dpc4 tumor suppressor gene engenders a distinct class of pancreatic tumors, mucinous cystic neoplasms (MCNs), which culminate in invasive ductal adenocarcinomas. | pancreatic,neoplasm, |
| combined with screening of K-ras mutations and allelic losses of tumor suppressors p16 and DPC4 represents a very sensitive approach in screening for pancreatic malignancy. | pancreatic, |
| Results define a molecular mechanism that explains how loss of the tumor suppressor Smad4 promotes colorectal cancer progression | colorectal, |
| Aberrant TGF??/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancer. | ovarian, |
| Smad4 may reduce lymphangiogenesis of colon cancer cell by attenuating VEGF-C secretion and act as tumor suppressor by inhibiting migration, invasion and tumorigenicity. | colorectal, |
| Studies establish Smad4 as a lung tumor suppressor and suggest that the defective DNA repair phenotype of Smad4-deficient tumors can be exploited by specific therapeutic strategies. | lung, |
| MZF1 has a role in cellular migration of gastric cancer cells via promoting an increase in intracellular SMAD4 levels. This study might provide new evidence for the molecular basis of the tumor suppressive effect of the MZF1-SMAD4 axis, a new therapeutic target in advanced human gastric cancer. | gastric, |
| mechanistic study revealed that miR-224 functions by inhibiting the tumor suppressor, SMAD4, to support the proliferation and migration of osteosarcoma (OS) cells. Our findings indicate that targeting TAZ and miR-224 could be a promising approach for the treatment of OS. | osteosarcoma, |
| this study supports the key role of SMAD4 as a tumour suppressor gene in pancreatic ductal adenocarcinoma and shows that SMAD4 Y353C is associated with poor progression of pancreatic ductal adenocarcinoma | pancreatic, |
| Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4. | None |
| Activation of transforming growth factor-beta signaling by SUMO-1 modification of tumor suppressor Smad4/DPC4. | None |
| Differential ubiquitination defines the functional status of the tumor suppressor Smad4. | None |
| SUMO-1/Ubc9 promotes nuclear accumulation and metabolic stability of tumor suppressor Smad4. | None |